IL246002D0 - Novel methods - Google Patents

Novel methods

Info

Publication number
IL246002D0
IL246002D0 IL246002A IL24600216A IL246002D0 IL 246002 D0 IL246002 D0 IL 246002D0 IL 246002 A IL246002 A IL 246002A IL 24600216 A IL24600216 A IL 24600216A IL 246002 D0 IL246002 D0 IL 246002D0
Authority
IL
Israel
Prior art keywords
novel methods
novel
methods
Prior art date
Application number
IL246002A
Other languages
Hebrew (he)
Original Assignee
Intra-Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361911416P priority Critical
Priority to US201461925607P priority
Priority to US201461975702P priority
Priority to US201462032326P priority
Priority to PCT/US2014/068443 priority patent/WO2015085004A1/en
Application filed by Intra-Cellular Therapies Inc filed Critical Intra-Cellular Therapies Inc
Publication of IL246002D0 publication Critical patent/IL246002D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
IL246002A 2013-12-03 2016-06-02 Novel methods IL246002D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US201361911416P true 2013-12-03 2013-12-03
US201461925607P true 2014-01-09 2014-01-09
US201461975702P true 2014-04-04 2014-04-04
US201462032326P true 2014-08-01 2014-08-01
PCT/US2014/068443 WO2015085004A1 (en) 2013-12-03 2014-12-03 Novel methods

Publications (1)

Publication Number Publication Date
IL246002D0 true IL246002D0 (en) 2016-07-31

Family

ID=53274093

Family Applications (1)

Application Number Title Priority Date Filing Date
IL246002A IL246002D0 (en) 2013-12-03 2016-06-02 Novel methods

Country Status (11)

Country Link
US (4) US9956227B2 (en)
EP (1) EP3076967A4 (en)
JP (2) JP6475727B2 (en)
KR (1) KR20160093055A (en)
CN (1) CN105939712A (en)
AU (2) AU2014360452C1 (en)
CA (1) CA2932610A1 (en)
IL (1) IL246002D0 (en)
MX (1) MX2016007219A (en)
RU (1) RU2682658C1 (en)
WO (1) WO2015085004A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009009773A (en) 2007-03-12 2009-12-16 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis.
MX2010013020A (en) * 2008-05-27 2011-03-21 Intra Cellular Therapies Inc Methods and compositions for sleep disorders and other disorders.
ES2602503T3 (en) 2010-04-22 2017-02-21 Intra-Cellular Therapies, Inc. organic compounds
AU2013245702A1 (en) 2012-04-14 2014-11-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
EP3076967A4 (en) 2013-12-03 2017-05-10 Intra-Cellular Therapies, Inc. Novel methods
WO2015154025A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2015154030A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10034859B2 (en) * 2015-07-15 2018-07-31 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
WO2017132408A1 (en) 2016-01-26 2017-08-03 Intra-Cellular Therapies, Inc. Organic compounds
EP3436016A4 (en) * 2016-03-28 2019-09-18 Intra Cellular Therapies Inc Novel co-crystals
WO2019023063A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Organic compounds
KR20190049207A (en) 2017-11-01 2019-05-09 한국화학연구원 A sustained-release injection of microspheres containing escitalopram and manufacturing method thereof
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
IE41352B1 (en) 1974-04-01 1979-12-19 Pfizer 5-aryl-1,2,3,4-tetrahydro- -carbolines
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4522944A (en) 1982-12-23 1985-06-11 Erba Farmitalia Carboxamido-derivatives of 5H-1,3,4-thiadiazolo[3,2-a]pyrimidines, compositions and use
CH656884A5 (en) 1983-08-26 1986-07-31 Sandoz Ag Polyol esters, their preparation and use.
DE3786185T2 (en) 1986-03-19 1993-10-21 Kumiai Chemical Industry Co 5H-1,3,4-thiazolo [3,2-a] pyrimidin-5-one derivatives and fungicidal compositions containing them.
JP2641443B2 (en) 1986-04-07 1997-08-13 イハラケミカル工業株式会社 5H-1,3,4-thiadiazolo [3,2-a] pyrimidine-5-one derivatives and agricultural and horticultural fungicides as an active ingredient which
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
IT1271352B (en) 1993-04-08 1997-05-27 Boehringer Ingelheim Italia indole derivatives useful in the treatment of central nervous system disorders
KR100354270B1 (en) 1993-11-19 2003-02-11 알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii The microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazole, and 1,2-benz isothiazole
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
US5648539A (en) 1996-02-29 1997-07-15 Xerox Corporation Low temperature arylamine processes
US5648542A (en) 1996-02-29 1997-07-15 Xerox Corporation Arylamine processes
US5654482A (en) 1996-02-29 1997-08-05 Xerox Corporation Triarylamine processes
US5847166A (en) 1996-10-10 1998-12-08 Massachusetts Institute Of Technology Synthesis of aryl ethers
US20010008942A1 (en) 1998-12-08 2001-07-19 Buchwald Stephen L. Synthesis of aryl ethers
US5705697A (en) 1997-01-30 1998-01-06 Xerox Corporation Arylamine processes
US5723669A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
US5723671A (en) 1997-01-30 1998-03-03 Xerox Corporation Arylamine processes
TWI242011B (en) 1997-03-31 2005-10-21 Eisai Co Ltd 1,4-substituted cyclic amine derivatives
US6323366B1 (en) 1997-07-29 2001-11-27 Massachusetts Institute Of Technology Arylamine synthesis
GB2328686B (en) 1997-08-25 2001-09-26 Sankio Chemical Co Ltd Method for producing arylamine
US6395939B1 (en) 1997-10-06 2002-05-28 Massachusetts Institute Of Technology Diaryl ether condensation reactions
ES2257864T3 (en) 1998-07-10 2006-08-01 Massachusetts Institute Of Technology Ligands for metals and metal catalyzed improved processes based thereon.
WO1999043643A2 (en) 1998-02-26 1999-09-02 Massachusetts Institute Of Technology Metal-catalyzed arylations and vinylations of hydrazines, hydrazones, hydroxylamines and oximes
US6235936B1 (en) 1998-02-26 2001-05-22 Massachusetts Institute Of Technology Metal-catalyzed arylations of hydrazines, hydrazones, and related substrates
US5902901A (en) 1998-05-07 1999-05-11 Xerox Corporation Arylamine processes
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
PT1140012E (en) 1998-12-17 2004-05-31 Alza Corp Conversation of full gelatine capsules with liquid in libertacao systems controlled by multiple layers
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
AR023574A1 (en) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Azepinindol tetracyclic compounds, pharmaceutical compositions and the use of such compounds for preparing a medicament, and intermediaries
MXPA01012914A (en) 1999-06-15 2004-04-21 Squibb Bristol Myers Co Substituted heterocycle fused gamma-carbolines.
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6541639B2 (en) 2000-07-26 2003-04-01 Bristol-Myers Squibb Pharma Company Efficient ligand-mediated Ullmann coupling of anilines and azoles
RU2003121304A (en) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Substituted pyridoindole as serotonin agonists and antagonists
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
DK2275395T3 (en) 2001-04-24 2017-02-20 Massachusetts Inst Of Tech (Mit) Copper-catalyzed provision of carbon-carbon compounds.
JP2005526691A (en) 2001-08-08 2005-09-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Therapeutic agents 1H- pyrido [4,3-b]
EP1314554A1 (en) 2001-11-23 2003-05-28 Kba-Giori S.A. Removing device for security-elements
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
MXPA05001191A (en) 2002-07-29 2005-09-12 Johnson & Johnson Methods and dosage forms for controlled delivery of paliperidone.
WO2004013094A2 (en) 2002-08-02 2004-02-12 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
AU2003287433A1 (en) 2002-11-01 2004-06-07 Oregon Health And Science University Treatment of hyperkinetic movement disorder with donepezil
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
JP4486505B2 (en) 2002-12-19 2010-06-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Substituted tricyclic gamma-carboline compounds as serotonin receptor agonists and antagonists
EP2009000B1 (en) * 2003-01-16 2011-06-08 Acadia Pharmaceuticals Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
RU2006106429A (en) 2003-07-21 2006-08-27 СмитКлайн Бичем Корпорейшн (US) Salt of (2s, 4s) -4-fluoro-1- (4-fluoro-beta- (4-fluorophenyl) -l-phenylalanyl) -2-pirrolidinkarbonitrila with p-toluenesulfonic acid and anhydrous crystalline forms of
JP2005259113A (en) 2004-02-12 2005-09-22 Ricoh Co Ltd Process editing apparatus, process management apparatus, process editing program, process management program, recording medium, process editing method and process management method
CA2564018A1 (en) 2004-03-05 2005-10-13 Pharma C S.A. 8-phenoxy-.gamma. carboline derivatives
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
CA2580619C (en) 2004-09-20 2013-11-12 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
WO2006032999A1 (en) 2004-09-21 2006-03-30 Pfizer Products Inc. N-methyl hydroxyethylamine useful in treating cns conditions
US7614727B2 (en) 2004-09-30 2009-11-10 Fujifilm Corporation Liquid ejection head, manufacturing method thereof, and image forming apparatus
BRPI0519054A2 (en) 2004-12-15 2008-12-23 Hoffmann La Roche Substituted bicyclic and tricyclic phenyl methanones as glycine transporter (glyt-1) inhibitors for the treatment of alzheimer's disease
BRPI0607239A2 (en) 2005-01-25 2009-08-25 Celgene Corp uses of a therapeutically or prophylactically effective amount of (3r) -4-amino-2-4-amino-2- (3-methyl-2,6-dioxopiperidin-3-yl) -isoindol-1,3-dione - (3-methyl-2,6-dioxopiperidin-3-yl) isoindol-1,3-dione, and (3s) -4-amino-2- (3-methyl-2,6-dioxopiperidin-3-one) il) -isoindol-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical composition, and single unit dosage form
JP5186219B2 (en) * 2005-01-25 2013-04-17 エピックス デラウェア, インコーポレイテッド Substituted arylamine compounds and their use as 5-HT6 modulators
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc Organic compounds for treating reduced dopamine receptor signalling activity
AU2007206016A1 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
KR20090064418A (en) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 Combinations containing a 4-acylaminopyridine derivative
MX2009009773A (en) 2007-03-12 2009-12-16 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis.
BRPI0815850A2 (en) 2007-08-01 2014-10-07 Medivation Neurology Inc "method for treating, delaying progress, preventing or delaying the development of schizophrenia in an individual, pharmaceutically acceptable composition, kit and method to enhance an individual answer"
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2009097688A1 (en) 2008-02-05 2009-08-13 Clera Inc. Compositions and methods for alleviating depression or improving cognition
AU2009223701B2 (en) 2008-03-12 2015-04-16 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines solid
MX2010013020A (en) * 2008-05-27 2011-03-21 Intra Cellular Therapies Inc Methods and compositions for sleep disorders and other disorders.
US8309772B2 (en) 2008-07-31 2012-11-13 Celanese International Corporation Tunable catalyst gas phase hydrogenation of carboxylic acids
ES2602503T3 (en) 2010-04-22 2017-02-21 Intra-Cellular Therapies, Inc. organic compounds
AU2013245702A1 (en) 2012-04-14 2014-11-13 Intra-Cellular Therapies, Inc. Organic compounds
BR112015005743A2 (en) 2012-09-14 2017-07-04 Abbvie Deutschland tricyclic quinoxaline and quinoline derivatives
WO2014145192A1 (en) * 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
EP3076967A4 (en) 2013-12-03 2017-05-10 Intra-Cellular Therapies, Inc. Novel methods
WO2015154025A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2015154030A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
CA2987114A1 (en) 2015-06-03 2016-12-08 Triastek, Inc. Dosage forms and use thereof
WO2017132408A1 (en) 2016-01-26 2017-08-03 Intra-Cellular Therapies, Inc. Organic compounds
BR112018069594A2 (en) 2016-03-25 2019-01-29 Intra Cellular Therapies Inc organic compounds
WO2017165755A1 (en) 2016-03-25 2017-09-28 Intra-Cellular Therapies, Inc. Organic compounds

Also Published As

Publication number Publication date
AU2014360452C1 (en) 2019-05-16
CA2932610A1 (en) 2015-06-11
US9956227B2 (en) 2018-05-01
JP6475727B2 (en) 2019-02-27
JP2019077724A (en) 2019-05-23
EP3076967A4 (en) 2017-05-10
KR20160093055A (en) 2016-08-05
JP2016539144A (en) 2016-12-15
WO2015085004A1 (en) 2015-06-11
AU2014360452A1 (en) 2016-07-21
US20190298730A1 (en) 2019-10-03
MX2016007219A (en) 2016-09-16
US20180200256A1 (en) 2018-07-19
AU2019200301A1 (en) 2019-02-07
AU2014360452B2 (en) 2018-10-18
US20160310502A1 (en) 2016-10-27
US10322134B2 (en) 2019-06-18
RU2682658C1 (en) 2019-03-20
CN105939712A (en) 2016-09-14
US20190290655A1 (en) 2019-09-26
EP3076967A1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
AU354395S (en) Case
GB201311001D0 (en) Lucabella
GB201413149D0 (en) No details
AU354443S (en) Case
AU355447S (en) Case
HK1222846A1 (en) Substituted benzylpyrazoles
GB201314695D0 (en) Method
HK1221717A1 (en) Substituted benzylpyrazoles
PL2953956T3 (en) Heteropolyoxometalates
IL246002D0 (en) Novel methods
SG11201601939VA (en) Method
EP2957205A4 (en) Hand-dryer
EP2956141A4 (en) Novel uses
GB2514689B (en) Quick-Coupler
HRP20181775T1 (en) Arylquinazolines
EP3000028A4 (en) Auto-calendaring
HK1203409A1 (en) Complex
ZA201505682B (en) Microanchor
GB201312133D0 (en) Immunotherapy
IL242777A (en) Construction-set elements
GB201317802D0 (en) SmartHaler patent application
GB201301233D0 (en) Method
GB201318465D0 (en) Method
GB201309057D0 (en) Method
GB201401963D0 (en) Process